Your shopping cart is currently empty

Synonyms: 5-(4-Hydroxybenzylidene)-2-iminothiazolidin-4-one

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $40 | In Stock | In Stock | |
| 10 mg | $65 | In Stock | In Stock | |
| 25 mg | $121 | - | In Stock | |
| 50 mg | $180 | - | In Stock | |
| 100 mg | $265 | - | In Stock | |
| 200 mg | $392 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $44 | In Stock | In Stock |
| Description | Mirin is a Mre11-Rad50-Nbs1 (MRN) complex inhibitor that inhibits MRN-dependent ATM activation without affecting ATM protein kinase activity. It also inhibits Mre11-associated exonuclease activity, thereby disrupting DNA double-strand break repair.Mirin induces cell cycle arrest in G1 phase. |
| In vitro | Mirin inhibits H2AX phosphorylation with an IC50 value of 66 μM. Mirin inhibits ATM-dependent phosphorylation of downstream targets Nbs1 and Chk2 as well as MRN-dependent ATM autophosphorylation at Ser1981 in response to DSBs. Mirin treatment (50, 100 μM) of TOSA4 cells induced a significant G2 arrest. Mirin (10-100 μM) inhibits homology-dependent DNA repair in TOSA4 cells. [1] |
| Synonyms | 5-(4-Hydroxybenzylidene)-2-iminothiazolidin-4-one |
| Molecular Weight | 220.25 |
| Formula | C10H8N2O2S |
| Cas No. | 299953-00-7 |
| Smiles | O=C1N=C(SC1=CC2=CC=C(O)C=C2)N |
| Storage | Keep away from direct sunlight,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 83.3 mg/mL (378.21 mM), Sonication is recommended. DMF: 60 mg/mL (272.42 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8.33 mg/mL (37.82 mM), Solution. 10% DMSO+90% Saline: < 8.33 mg/mL (37.82 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMF/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.